Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration - PubMed (original) (raw)
. 2000 May 4;43(9):1664-9.
doi: 10.1021/jm9909645.
Affiliations
- PMID: 10794683
- DOI: 10.1021/jm9909645
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
L B Knudsen et al. J Med Chem. 2000.
Abstract
A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC(50)) of 55 pM for the cloned human GLP-1 receptor. Many of the compounds had similar or even higher potencies, despite quite large substituents. All compounds derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients. A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency. Derivatization with two fatty acid substituents led to a considerable loss of potency. A structure-activity relationship on derivatization of specific amino acids generally was obtained. It was found that the longer the fatty acid, the more potency was lost. Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.
Similar articles
- Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR. Green BD, et al. Biol Chem. 2004 Feb;385(2):169-77. doi: 10.1515/BC.2004.035. Biol Chem. 2004. PMID: 15101559 - Therapeutic strategies based on glucagon-like peptide 1.
Deacon CF. Deacon CF. Diabetes. 2004 Sep;53(9):2181-9. doi: 10.2337/diabetes.53.9.2181. Diabetes. 2004. PMID: 15331525 Review. - Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB. Xiao Q, et al. Biochemistry. 2001 Mar 6;40(9):2860-9. doi: 10.1021/bi0014498. Biochemistry. 2001. PMID: 11258897 - Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Nauck MA, et al. Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981. Am J Physiol. 1997. PMID: 9374685 Clinical Trial. - The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ, Nauck MA. Meier JJ, et al. Curr Opin Investig Drugs. 2004 Apr;5(4):402-10. Curr Opin Investig Drugs. 2004. PMID: 15134281 Review.
Cited by
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.
Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, Altowarqi NA, Alzahrani H, Alshehri AM, Alkhaldi RK, Alqahtani KW, Alharbi NH, Alhulayfi HF, Sharifi SY, Dighriri IM. Hamed K, et al. Cureus. 2024 Sep 1;16(9):e68390. doi: 10.7759/cureus.68390. eCollection 2024 Sep. Cureus. 2024. PMID: 39355484 Free PMC article. Review. - Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity.
Parums DV. Parums DV. Med Sci Monit. 2024 Oct 1;30:e946675. doi: 10.12659/MSM.946675. Med Sci Monit. 2024. PMID: 39350608 Free PMC article. - QnAs with Svetlana Mojsov, Joel Habener, and Lotte Bjerre Knudsen: Winners of the 2024 Lasker~DeBakey Clinical Medical Research Award.
Nair P. Nair P. Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2416868121. doi: 10.1073/pnas.2416868121. Epub 2024 Sep 19. Proc Natl Acad Sci U S A. 2024. PMID: 39297682 Free PMC article. No abstract available. - The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.
Friedman JM. Friedman JM. Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2415550121. doi: 10.1073/pnas.2415550121. Epub 2024 Sep 19. Proc Natl Acad Sci U S A. 2024. PMID: 39297680 Free PMC article. - Structure-Based Computational Scanning of Chemical Modification Sites in Biologics.
Thomas N, Sanyal T, Greisen P Jr, Deibler K. Thomas N, et al. ACS Omega. 2024 Aug 14;9(34):36787-36794. doi: 10.1021/acsomega.4c05857. eCollection 2024 Aug 27. ACS Omega. 2024. PMID: 39220547 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases